Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.93 USD | +7.05% | +11.02% | +63.38% |
Apr. 19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
Mar. 28 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
Business Summary
Number of employees: 201
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Therapeutics
100.0
%
| 42 | 100.0 % | 44 | 100.0 % | +5.68% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Netherlands
100.0
%
| 42 | 100.0 % | 44 | 100.0 % | +5.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bill Lundberg
CEO | Chief Executive Officer | 60 | 19-06-11 |
Gregory Perry
DFI | Director of Finance/CFO | 63 | 16-04-30 |
Chief Tech/Sci/R&D Officer | - | 16-11-30 | |
Chief Tech/Sci/R&D Officer | 56 | 21-04-30 | |
Andrew Joe
CTO | Chief Tech/Sci/R&D Officer | 58 | 20-07-26 |
Peter Silverman
COO | Chief Operating Officer | 46 | 17-01-31 |
John de Kruif
CTO | Chief Tech/Sci/R&D Officer | 60 | 07-03-31 |
Sherri L. Spear
IRC | Investor Relations Contact | - | - |
Ashley Pereira
LAW | General Counsel | - | 21-08-31 |
Shannon Campbell
PRN | Corporate Officer/Principal | - | 22-01-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gregory Perry
DFI | Director of Finance/CFO | 63 | 16-04-30 |
Maxine Gowen
BRD | Director/Board Member | 66 | 21-05-27 |
Paolo Pucci
BRD | Director/Board Member | 63 | 20-06-29 |
Anand Mehra
CHM | Chairman | 48 | 15-08-25 |
Mark Iwicki
BRD | Director/Board Member | 57 | 15-04-30 |
Bill Lundberg
CEO | Chief Executive Officer | 60 | 19-06-11 |
Victor Sandor
BRD | Director/Board Member | 57 | 19-06-11 |
Len Kanavy
BRD | Director/Board Member | 62 | 18-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 58,687,551 | 54,301,344 ( 92.53 %) | 0 | 92.53 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.38% | 2.46B | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- MRUS Stock
- Company Merus N.V.